Login | Register

Sector: Life Sciences

Software, electronics and semiconductors most transacted assets in Q3 2023
Software, electronics and semiconductors most transacted assets in Q3 2023

The latest AST Patent Deals Report shows assets being transacted by the likes of Huawei and Intel on the sell side, and Philips and Softbank on the buy side

Eligibility and PTAB reform bills spark debate at IAM event
Eligibility and PTAB reform bills spark debate at IAM event

IAM Connect: Patent Policy and Litigation delved deeply into Section 101 legislation, reform efforts at the Patent Trial and Appeal Board, and reactions to the European Commission's SEP proposal

Life Sciences correspondent

Thought leadership from industry experts

Latest updates

EPO Enlarged Board of Appeal confirms use of post-published data to support inventive step
Latest content

Three things to know about the US government’s new strategy for standards development

Here’s the critical background to know as innovators today participate in a USPTO listening session about the intersection between standards development and IP

20 September 2023

Unified Patent Court grants preliminary injunction to 10x Genomics

A preliminary injunction strikes a heavy blow against NanoString Technologies which already withdrew from Germany due to a previous 10x injunction and now must do so from 16 more European countries

19 September 2023

Patent transactions in Q2 2023

Featured in Secondary Market Activity

The surge is due to 9,702 US patent assets involved in the BlackBerry sale to Key Patent Innovations, which runs Malikie Innovations, according to the AST Patent Deals Report for Q2 2023

15 September 2023

10x Genomics strikes blow against NanoString in the US

IAM explores the American portions of a spat whose UPC and German actions have hogged the limelight

14 September 2023

‘Live or die’: LG Chem prepares to launch series of disputes as strategy pivots, reveals IP head

The Korean chemicals giant will do anything to combat “harsh competition” and IP is one of the “crucial” tools for securing success, contends IP head Kyung-Hwa Min

13 September 2023

$227 million Apollo Therapeutics investment is a major boost for innovative tech transfer approach

Pathbreaking joint venture between academia and Big Pharma addresses university IP monetisation challenges

12 September 2023

RegenxBio/Sarepta dispute highlights strategic challenges for gene therapy developers

Narrow safe harbor immunity and platform technology patents are creating both pitfalls and opportunities

08 September 2023

JS Held expands Ocean Tomo IP practice with new acquisition

The global scientific and engineering consultancy has bought TechPats, a patent-focused technical expert firm, at a time when an uncertain economy and declining number of M&As has led some companies to issue layoff notices to IP staff

07 September 2023

UPC holds first ever preliminary injunction hearing

NanoString Technologies is facing an injunction at the UPC, which has scheduled several further PI hearings in Munich and Vienna

06 September 2023

Delhi High Court clarifies scope of product-by-process claims in landmark pharma ruling

In a first-of-its-kind judgment, the Delhi High Court has refused to grant an interim injunction against the defendants, stating that their process did not infringe the plaintiff’s patent that had constituted a ‘product-by-process’ claim. The patent community is hoping for a more detailed order after the trial, as this will provide much-needed clarity on the scope of product-by-process claims.

06 September 2023

Unlock unlimited access to all IAM content

Subscribe Now